U.S. markets closed

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.19-2.35 (-5.16%)
At close: 4:00PM EST

43.00 -0.19 (-0.44%)
After hours: 4:06PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close45.54
Open47.21
Bid43.02 x 2900
Ask43.13 x 900
Day's Range39.13 - 47.17
52 Week Range8.51 - 129.71
Volume1,475,523
Avg. Volume1,958,293
Market Cap1.135B
Beta (5Y Monthly)2.93
PE Ratio (TTM)N/A
EPS (TTM)-3.55
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Arcturus Therapeutics: Q4 Earnings Insights

    Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 64.47% over the past year to ($1.25), which missed the estimate of ($0.88). Revenue of $2,238,000 declined by 24.60% year over year, which missed the estimate of $2,360,000. Looking Ahead Earnings guidance hasn't been issued by the company for now. Arcturus Therapeutics hasn't issued any revenue guidance for the time being. Conference Call Details Date: Mar 01, 2021 View more earnings on ARCT Time: 04:30 PM ET Webcast URL: http://public.viavid.com/player/index.php?id=143486 Price Action 52-week high: $129.71 Company's 52-week low was at $8.51 Price action over last quarter: Up 37.13% Company Description Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 1, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Arcturus Therapeutics Holdings Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.